New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B—a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Xia, Y. & Liang, T. J. Gastroenterology 156, 311–324 (2019).
Raimondo, G. et al. J. Hepatol. 71, 397–408 (2019).
Loomba, R., Liang, T. J. & Hepatitis, B. Gastroenterology 152, 1297–1309 (2017).
Chen, C. J. & Yang, H. I. J. Gastroenterol. Hepatol. 26, 628–638 (2011).
Yuen, M.-F. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01513-4 (2021).
van den Berg, F. et al. Viruses 12, 851 (2020).
Werle-Lapostolle, B. et al. Gastroenterology 126, 1750–1758 (2004).
Allweiss, L. & Dandri, M. Viruses 9, 156 (2017).
Bertoletti, A. & Ferrari, C. Gut 61, 1754–1764 (2012).
Vaillant, A. Gastroenterology 160, 967–968 (2021).
Junt, T. & Barchet, W. Nat. Rev. Immunol. 15, 529–544 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Liang, T.J. Hepatitis B: a new weapon against an old enemy. Nat Med 27, 1672–1673 (2021). https://doi.org/10.1038/s41591-021-01512-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01512-5